Stem cell therapy for knee osteoarthritis is the most-studied application, with moderate evidence for pain reduction and some signs of structural improvement. Cost ranges €20,000–€50,000; outcomes vary based on disease stage and patient selection.
The knee is the poster child for stem cell regenerative medicine—well-suited anatomy, accessible for injection, clear pathology (cartilage loss), measurable outcomes (pain, function, MRI structural changes), and patient demand. More clinical trials have tested stem cell knee therapy than any other joint or tissue condition. The evidence is imperfect but substantially stronger than for autism, anti-ageing, or systemic "rejuvenation" claims. A patient with symptomatic knee osteoarthritis has genuine reason to consider stem cell therapy, though expectations must be calibrated carefully.
What does the evidence show? Meta-analyses of clinical trials—mostly small, some with weak controls—suggest that intra-articular (into the joint space) injection of mesenchymal stem cells produces pain reduction in roughly 60–75% of treated patients. Pain improvement is typically modest (30–50% reduction rather than elimination) and peaks at 3–6 months, though benefits often persist through 12 months in responders. Some studies report structural improvements on MRI: cartilage thickness increase or defect size reduction, though these are observed in 30–40% of treated patients, not universally. Responders report improved function: walking further, climbing stairs more easily, reduced reliance on pain medication.
Patient selection is critical. Stem cell therapy works better in early-stage osteoarthritis (mild to moderate cartilage loss) than in advanced disease (bone-on-bone contact, severe joint space narrowing). A patient in their 50s with early arthritis from a past sports injury has a better prognosis than a 75-year-old with decades of wear and inflammatory arthritis. Body weight matters; obese patients (BMI >35) have lower success rates partly because mechanical load on the knee outpaces any structural repair the cells might provide. Most published successes come from patients aged 30–70, with early-to-moderate disease, and BMI <30. If you fit outside this profile, success odds drop.
Treatment protocols vary. Some clinics inject cells directly into the joint (intra-articular); others use an intravenous route, betting that systemically infused cells home to the damaged area. Intra-articular is more anatomically direct and has better evidence. Some clinics culture your own bone marrow (autologous, weeks-long, expensive) versus using cultured allogeneic cells (faster, cheaper). Both approaches have supporting data; the choice depends on your timeline and budget. Cell dose varies (20 million to 500 million cells), and higher doses correlate modestly with better outcomes, though the relationship isn't linear.
Cost ranges significantly: Bulgarian clinics quote €20,000–€32,000; Western European clinics €45,000–€65,000. Insurance rarely covers stem cell therapy for osteoarthritis, treating it as experimental even where evidence is substantial. Most patients pay out-of-pocket. Before committing, insist on baseline MRI, a detailed explanation of your disease stage, a realistic discussion of success probability given your age and severity, and a structured follow-up protocol with repeat imaging at 6 and 12 months. Learn more about the procedure, and assess candidacy based on your specific situation.
Educational content; outcomes vary by patient and most uses are investigational — consult a physician. Reviewed by the StemCellAtlas editorial team.
StemCellAtlas is your guide to stem-cell therapy: what the evidence shows, which conditions are treated, and the real all-in cost by country — typically €3,000–8,000 with our partner Stem Plus (Sofia), Europe's lowest-cost EU destination, versus $15,000–35,000 in the US.
Get an honest assessment